Amgen signs US deal with DxS for TheraScreen

DxS, a UK diagnostics firm, has signed an agreement with US biotechnology major Amgen to provide a K-RAS companion diagnostic for the latter's Vectibix (panitumumab) in the USA.

Under the terms of the agreement, the firms will work together to further facilitate the use of Vectibix in metastatic colorectal cancer patients with wild-type K-RAS status, with the intent that DxS' TheraScreen: K-RAS Mutation Kit will become a companion diagnostic for use with Vectibix if approved by the US Food and Drug Administration. The agreement follows a collaboration entered into by the parties last year with respect to the TheraScreen in Europe.